ILKN421H

iLeukon Therapeutics, Inc. · Phase 2 active Small molecule

At a glance

Generic name	ILKN421H
Sponsor	iLeukon Therapeutics, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ILKN421H CI brief — competitive landscape report
ILKN421H updates RSS · CI watch RSS
iLeukon Therapeutics, Inc. portfolio CI